....well researched good first article. A few quick comments. *I too am "iffy" on the NCE. *Lovaza going generic will have an effect. Some will use it because they cannot afford AMR-101. I agree it will be negligible. *Even though a few docs will still prescribe lovaza to those that cannot afford ...MOST will immediately switch to AMR-101. To not do so would be negligent. *If successful in gaining approval for marine cohorts the off-label use in those with the lower TG counts will be TREMENDOUS. Side effects for AMR-101 are virtually nil...upset stomach for some. *The side effects for statins are a completely different matter and I have seen SUBSTANTIAL anecdotal evidence of this first hand. The ability to lower statin use is a benefit that I feel is glossed over by most analysts. A tremendous benefit vs. lovaza. *IMHO almost all analysts are understating the mkt potential for AMR-101. Most patients do not understand that Lovaza raises LDL. Any physician "writing" for Lovaza after and IF AMR-101 is approved could arguably be considered negligent. A good attorney would RUN with the fact that a doc knowingly wrote for a product that knowingly raised LDL. I believe the number of docs that do not prescribe Lovaza for this reason may be understated. The REDUCE-IT study takes it to a completely different level.